Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors

Seminars in Oncology

Volumn 26, Issue 2 SUUPL., 1999, Pages 89-93

  Thodtmann, R ^a   Depenbrock, H ^a   Blatter, J ^a   Johnson, R D ^a   Van Oosterom, A ^a   Hanauske, A R ^a  

^a Center for Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CISPLATIN; LOMETREXOL; PEMETREXED;

ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG URINE LEVEL; FATIGUE; HEAD AND NECK CARCINOMA; HUMAN; HYDRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MESOTHELIOMA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; ENZYME INHIBITORS; FEMALE; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED;

EID: 0032964125     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)